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Introduction {#sec005}
============

Triple negative breast cancer (TNBC) is defined as hormone receptor negative and HER2 receptor negative breast cancer, which comprises approximately 10% to 25% of breast cancer molecular subtypes \[[@pone.0197523.ref001]--[@pone.0197523.ref003]\]. Due to the lack of a therapeutic target, TNBC has a worse prognosis when compared to other molecular subtypes of breast cancer \[[@pone.0197523.ref004]\]. Therefore, the current therapeutic strategy for adjuvant therapy of TNBC is systemic chemotherapy, which can improve prognosis of TNBC patients.

Recently, there has been a steady increase in the incidence of T1N0 breast cancer due to accessible breast cancer screening programs in Korea \[[@pone.0197523.ref005],[@pone.0197523.ref006]\]. Among patients with T1N0 breast cancers, the prevalence of patients with T1c stage is higher than that of patients with T1a or T1b stage \[[@pone.0197523.ref007]\]. Therefore, it is of clinical importance to determine the optimal treatment guidelines for patient with T1c stage TNBC breast malignancies.

Historically, the most utilized adjuvant chemotherapy regimen in Korea for T1N0 breast cancer was an adriamycin-containing regimen (either concurrent use of adriamycin plus cyclophosphamide \[AC\] or adriamycin/epirubicin plus cyclophosphamide plus 5-FU \[FAC/FEC\]), or a non-adriamycin containing regimen (including concurrent use of cyclophosphamide plus 5-FU plus methotrexate \[CMF\]). In the current national comprehensive cancer network (NCCN) guideline, there is a category 1 recommendation of adjuvant systemic chemotherapy including AC, FAC/FEC, or CMF regimens for node negative T1c TNBC patient. However, there are few clinical studies investigating the prognostic role of adjuvant chemotherapy in node negative T1c TNBC patient.

In this study, the prognostic role of adjuvant systemic chemotherapy in node negative, T1c TNBC breast cancer was investigated using a large cohort from the Korean breast cancer registry (KBCR). In addition, the prognostic effect between AC, FAC/FEC, and CMF regimens is compared in node-negative T1c breast cancer by subgroup analysis.

Methods {#sec006}
=======

The Korean breast cancer registry {#sec007}
---------------------------------

The KBCR is a nationwide database that includes patient data from 41 university hospitals, as well as 61 surgical training hospitals \[[@pone.0197523.ref008]\]. This database includes clinicopathological information including: patient survival, sex, age, surgical methods administered, pathological characteristics of the tumor, any adjuvant treatment received, and stage of cancer (based on the 7^th^ American Joint Committee on Cancer classification). Recently, survival information of patients in the KBCR was updated, with the last follow up date for patient survival recorded on December 31, 2014.

Study cohort {#sec008}
------------

From the KBCR database, 34,499 potential study patients who were diagnosed with breast cancer between May 1980 and December 2010 were retrospectively reviewed. Among them, a total of 2,217 patients with T1c N0 M0 TNBC were identified. In order to confirm the TNBC status of potential study patients, the immunohistochemical results for HER2 status were reviewed and the fluorescence in situ hybridization assay findings were used to confirm the HER2 status if the immunohistochemical results for HER2/neu staining were inconclusive (2+). After confirmation of TNBC status, patients were excluded if they had multifocal or multicentric breast cancer, history of previous ipsilateral or contralateral breast cancer, primary cancer histology other than invasive ductal subtype, or had undergone neoadjuvant systemic therapy. In addition, patients who were not treated with curative intent, those lacking follow-up data, or those without sufficient adjuvant treatment information, were also excluded. After applying the exclusion criteria, 1,151 patients remained for inclusion in this study. All patients who were treated with breast conserving surgery received adjuvant radiotherapy. This study was approved by the Institutional Review Board of St. Vincent Hospital. All participants in this study provided written informed consent for storage of their medical information in the database and use of this information in research. All experiments complied with the current laws of Korea.

Patient treatment subgroups {#sec009}
---------------------------

Patients were categorized into four treatment groups dependent upon chemotherapy regimen: (1) no chemotherapy, (2) AC, (3) FAC/FEC, and (4) CMF. Patients in the AC group received 4 cycles of concurrent adriamycin + cyclophosphamide every 3 weeks. Patients in the FAC/FEC group received 6 cycles of concurrent 5-FU + Adriamycin/epirubicin + cyclophosphamide every 3 weeks. Patients in the CMF group received 6 cycles of concurrent 5-FU + methotrexate + cyclophosphamide every 4 weeks. The choice of systemic chemotherapy regimen was made at the clinician's discretion, with all patients completing the full cycle of chemotherapy according to the standard chemotherapy protocol at the time.

Statistical analyses {#sec010}
--------------------

The following clinicopathological characteristics were included in the analysis: age at diagnosis, surgery type for breast and axilla, number of total harvested lymph node, tumor size, histologic grade, lymphovascular invasion, and information for adjuvant treatment (including systemic chemotherapy, radiotherapy). The primary endpoint of this study was overall survival (OS). OS was defined as the period from the date of breast cancer diagnosis until the date of death from any cause or the date of last follow-up. Clinicopathological characteristic differences between the treatment subgroups were compared using the independent *t* test, Pearson's Chi-square test, or one-way analysis of variance. Survival curves were obtained using the Kaplan-Meier method, and significance was determined using the log-rank test. The multivariate analysis were conducted using Cox's proportional hazard regression model for survival, with the hazard ratio (HR) and 95% confidence interval (95% CI) estimated for each variable. Multivariate models were adjusted for age at diagnosis, surgery type for breast and axilla, tumor size, histologic grade, lymphatic invasion, and systemic chemotherapy regimen. All statistical tests were two-sided, and the statistical significance was set at *p* \< 0.05. All statistical analyses were performed using SPSS Statistics for Window, Version 12.0 (SPSS Inc., Chicago, IL, USA).

Results {#sec011}
=======

Study cohort {#sec012}
------------

Of the 1,151 patients included in the analysis, 1,006 received adjuvant chemotherapy while the remaining 145 received no chemotherapy. Among the 1,006 patients who received adjuvant chemotherapy, 586 received the AC regimen, 168 received the FAC/FEC regimen (42 FEC, 126 FAC), and 252 patients received the CMF regimen. The mean patient age was 49.11 ± 10.72 years (range, 22--80 years). The clinicopathological characteristics of the study cohort are shown in [Table 1](#pone.0197523.t001){ref-type="table"}.

10.1371/journal.pone.0197523.t001

###### Characteristics of the study cohort.

![](pone.0197523.t001){#pone.0197523.t001g}

                           No CTx.         AC              FAC/FEC   CMF                                                 
  ------------------------ --------------- --------------- --------- --------------- --------- --------------- --------- ---------
  **Age (years)**          55.14 ± 13.05   47.57 ± 9.68    \<0.001   46.51 ± 9.58    \<0.001   50.95 ± 10.72   0.001     \<0.001
  **≤50**                  58 (40.0%)      381 (65.0%)     \<0.001   116 (69.0%)     \<0.001   122 (48.4%)     0.105     \<0.001
  **\>50**                 87 (60.0%)      205 (35.0%)               52 (31.0%)                130 (51.6%)               
  **Surgery**                                                                                                            
  **BCS**                  95 (65.5%)      488 (83.3%)     \<0.001   141 (83.9%)     \<0.001   147 (58.3%)     0.158     \<0.001
  **Mastectomy**           50 (34.5%)      98 (16.7%)                27 (16.1%)                105 (41.7%)               
  **Axilla surgery**                                                                                                     
  **ALND**                 97 (66.9%)      330 (56.3%)     0.021     111 (66.1%)     0.905     218 (86.5%)     \<0.001   \<0.001
  **SLND**                 48 (33.1%)      256 (43.7%)               57 (33.9%)                34 (13.5%)                
  **Total harvest LN**     8.92 ± 7.514    7.36 ± 5.625    0.02      7.18 ± 6.398    0.03      13.24 ± 9.729   \<0.001   \<0.001
  **Tumor size (cm)**      1.593 ± 0.279   1.626 ± 0.277   0.198     1.652 ± 0.265   0.055     1.614 ± 0.277   0.473     0.368
  **1\<T±1.5**             77 (53.1%)      258 (44.0%)     0.05      67 (39.9%)      0.023     119 (47.2%)     0.259     0.331
  **1.5\<T±2**             68 (46.9%)      328 (56.0%)               101 (60.1%)               133 (52.8%)               
  **Histologic grade**                                                                                                   
  **G1**                   12 (8.3%)       14 (2.4%)       \<0.001   2 (1.2%)        \<0.001   27 (10.7%)      0.375     \<0.001
  **G2**                   53 (36.6%)      153 (26.1%)               28 (16.7%)                76 (30.2%)                
  **G3**                   80 (55.2%)      419 (71.5%)               138 (82.1%)               149 (59.1%)               
  **Lymphatic invasion**                                                                                                 
  **No**                   129 (89.0%)     522 (89.1%)     0.969     119 (70.8%)     \<0.001   223 (88.5%)     0.886     \<0.001
  **Yes**                  16 (11.0%)      64 (10.9%)                49 (29.2%)                29 (11.5%)                
  **Vascular invasion**                                                                                                  
  **No**                   134 (92.4%)     538 (91.8%)     0.811     159 (94.6%)     0.490     236 (93.7%)     0.637     0.374
  **Yes**                  11 (7.6%)       48 (8.2%)                 9 (5.4%)                  16 (6.3%)                 
  **Radiotherapy**                                                                                                       
  **No**                   47 (32.4%)      94 (16.0%)      \<0.001   25 (14.9%)      \<0.001   103 (40.9%)     0.094     \<0.001
  **Yes**                  98 (67.6%)      492 (84.0%)               143 (85.1%)               149 (59.1%)               

Data are presented as mean ± SD or n (%)

CTx, chemotherapy; BCS, breast conserving surgery; ALND, axillary lymph node dissection; SLND, sentinel lymph node dissection; LN, lymph node.

a\) P value for No CTx. vs. AC

b\) P value for No CTx. vs. FAC/FEC

c\) P value for No CTx. vs. CMF

d\) P value for AC vs. FAC/FEC vs. CMF

Overall, patients receiving adjuvant chemotherapy were younger than patients who did not receive chemotherapy. In addition, there were more patients under 50 years old in the AC and FAC/FEC regimen groups compared to the no chemotherapy group. When compared to the no chemotherapy group, patients receiving the AC and FAC/FEC regimens were more likely to have a higher tumor histologic grade, received breast conserving surgery, and received adjuvant radiotherapy. The sentinel lymph node dissection was more likely to be performed in the no chemotherapy group than the CMF regimen group. In addition, the total number of harvested lymph nodes was highest in the CMF regimen group, followed by the no chemotherapy group, and then both the AC and FAC/FEC groups. Tumor size showed no significant difference between the no chemotherapy group and each of the regimen groups, but patients with a tumor size larger than 1.5 cm were more prevalent in the FAC/FEC group compared to the no chemotherapy group. Lymphatic invasion was more common in the FAC/FEC group than the no chemotherapy group. There was no significant difference in the occurrence of vascular invasion between the treatment groups.

The baseline clinicopathological characteristics were compared between each chemotherapy regimen groups. Generally, patients in the CMF group, when compared to other chemotherapy regimen groups, were older and more likely to have received a mastectomy, axillary lymph node dissection, and have a higher total number of harvested lymph nodes. By contrast, patients in the AC and FAC/FEC group, when compared to the CMF group, were more likely to have a higher tumor histologic grade as well as received adjuvant radiotherapy. Patients in the FAC/FEC regimen group exhibited more frequent lymphatic invasion than the other chemotherapy regimen groups. There was no significant difference found in either tumor size or occurrence of vascular invasion between the chemotherapy regimen groups.

Survival outcomes for adjuvant chemotherapy {#sec013}
-------------------------------------------

The mean follow-up time of the study cohort was 87.98 ± 33.56 months (range, 6--192 months). During the follow-up period, the OS for study population was 91.66%, with death occurring in 96 patients. When the OS was analyzed between treatment regimens, patients in the no chemotherapy group showed significantly worse survival compared to all chemotherapy regimen groups: no chemotherapy vs. AC (85.5% vs. 92.0%, P = 0.041), no chemotherapy vs. FAC/FEC (85.5% vs. 94.0%, P = 0.023), and no chemotherapy vs. CMF (85.5% vs. 92.9%, P = 0.005) ([Fig 1A--1C](#pone.0197523.g001){ref-type="fig"}). However, when the OS was compared between each chemotherapy regimen group, there was no significant difference in OS between each chemotherapy regimen group ([Fig 2](#pone.0197523.g002){ref-type="fig"}).

![The association between adjuvant chemotherapy and overall survival.\
(a) No chemotherapy vs. AC regimen, (b) No chemotherapy vs. FAC/FEC regimen, (c) No chemotherapy vs. CMF regimen.](pone.0197523.g001){#pone.0197523.g001}

![The comparison between chemotherapy regimens in overall survival (AC regimen vs. FAC/FEC regimen vs. CMF regimen).](pone.0197523.g002){#pone.0197523.g002}

Multivariate analysis {#sec014}
---------------------

To further investigate the prognostic effect of adjuvant chemotherapy on node-negative T1c TNBC patients, a multivariate analysis of OS was performed ([Table 2](#pone.0197523.t002){ref-type="table"}). Patients in the no chemotherapy group consistently showed worse OS than each chemotherapy regimen group. However, there was no significant difference in OS between each chemotherapy regimen group.

10.1371/journal.pone.0197523.t002

###### Multivariate analysis for overall survival.

![](pone.0197523.t002){#pone.0197523.t002g}

  No CTx.   AC          FAC/FEC                CMF                                                                                         
  --------- ----------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- -------
  1.000     Reference   0.587 (0.350--0.984)   0.043                  0.427 (0.201--0.907)   0.027                  0.438 (0.232--0.828)   0.011
  --        1.000       Reference              0.639 (0.316--1.291)   0.212                  0.678 (0.377--1.221)   0.196                  

CTx, chemotherapy; HR, hazard ratio; CI, confidence interval.

Discussion {#sec015}
==========

In this study, the prognostic role of adjuvant chemotherapy in T1c node negative TNBC patients was investigated. In addition, the difference of prognostic effect was investigated between several commonly prescribed adjuvant chemotherapy regimens for T1c node negative TNBC. As a result, adjuvant chemotherapy was found to be beneficial for OS in T1c node negative TNBC patients. Furthermore, this beneficial effect was observed in each chemotherapy regimen investigated in this study (AC, FAC/FEC, and CMF regimens).

Previous studies reported worse prognosis of the TN subtype compared to other molecular subtypes in node negative early stage breast cancer \[[@pone.0197523.ref009]--[@pone.0197523.ref011]\]. Therefore, in these patients, the importance of adjuvant systemic chemotherapy to improve prognosis could be more pronounced in TNBC than other molecular subtypes. In this regard, several previous studies reported the prognostic implication of adjuvant chemotherapy in node negative early stage TNBC patients. In 2010, Colleoni et al. report a beneficial prognostic effect of adjuvant chemotherapy in node negative TNBC patients \[[@pone.0197523.ref012]\]. Another study by Kim et al. that included 4,033 node negative T1--2 TNBC patients, also reported higher OS in patients receiving adjuvant chemotherapy compared to those not receiving adjuvant chemotherapy \[[@pone.0197523.ref013]\]. However, because these studies did not exclusively contain patients with T1 stage, but also those with T2 stage, the prognostic benefit of the adjuvant chemotherapy remains unclear for patients with node negative TNBC T1 stage disease.

Some studies reported a prognostic effect from adjuvant chemotherapy in subcategorized T1 stage patients with the node negative TNBC subtype. In 2013, Migdady et al. and Olszewski et al. reported that adjuvant chemotherapy did not significantly improve patient survival in node negative TNBC for stage T1a or T1b disease. \[[@pone.0197523.ref014],[@pone.0197523.ref015]\]. Similarly, Vaz-Luis I et al. reported in 2014 that there was no significant prognostic effect of adjuvant chemotherapy in node negative TNBC patients, for either T1a or T1b stage \[[@pone.0197523.ref016]\]. Consequently, this lack of prognostic effect from adjuvant chemotherapy within the subcategorized T1 stage disease implies the need for further analysis separately between the T1a, T1b, and T1c stages.

The prognosis of T1c patients has been shown to be worse than T1a or T1b patients in previous studies. In 2009, Henry et al. report a higher recurrence rate in T1c patients compared to T1a for 110 node negative T1 TNBC subjects with a median 4.2 years follow-up (T1a 0% vs. T1c 8.2%) \[[@pone.0197523.ref017]\]. Additionally, Zachary et al. reported a lower disease-free survival of T1c as compared to T1mic, T1a, and T1b for 469 node negative T1 TNBC patients \[[@pone.0197523.ref018]\]. As a result of these studies, the current NCCN guideline strongly recommends adjuvant chemotherapy for T1c node negative TNBC patients because of their poor prognosis, despite no previous study exclusively investigating the prognostic effect of adjuvant chemotherapy for T1c node negative TNBC. To validate the current guideline, the prognostic effect of adjuvant chemotherapy was investigated exclusively in T1c node negative TNBC patients.

This was, to the best of our knowledge, the first study to investigate the prognostic effect of adjuvant chemotherapy in T1c node negative TNBC patients. There was one previous study that compared the prognostic effect between AC, FAC, and CMF regimens in node negative TNBC patients. In this study, Kim et al. reported a similar prognostic effect between AC, FAC, and CMF regimen in T1--2 node negative TNBC patients \[[@pone.0197523.ref013]\]. However, this study's cohort was relatively heterogeneous in terms of breast cancer progression, including T stage. This heterogeneity could have skewed the perceived efficacy of each chemotherapy regimen. In 2014, Wu et al. report the effect on survival from adjuvant CMF chemotherapy regimen according to tumor size in node negative TNBC patients \[[@pone.0197523.ref019]\]. Therefore, it is plausible that the effect on survival by each chemotherapy regimen could differ between subcategorized tumor size subgroups for T1 node negative TNBC patients. In our study, a relatively homogenous study cohort was utilized and found similar prognostic effect between AC, FAC/FEC, and CMF regimens for T1c node negative TNBC. From the results of this study, there is evidence to verify the guidelines recommending adjuvant chemotherapy for T1c node negative TNBC patients.

This study had several limitations, which should be considered. First, this study was retrospectively designed. There exists the possibility of selection or information bias. Second, because the information for tumor recurrence and cause of death was not available in the recently updated KBCR database, survival could not be investigated in terms of tumor recurrence or breast cancer specific events. Third, despite of the recent use of taxane-based chemotherapy regimens for early breast cancer, no such patient group was included in this study.

Conclusions {#sec016}
===========

This study showed that adjuvant systemic chemotherapy may improve patient OS in T1c node negative TNBC, regardless of AC, FAC/FEC, or CMF chemotherapy regimen administered. A larger future study is needed to validate this study's results.
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